TIMP-1/MMP-9 Imbalance in Brain Edema in Rats With Fulminant Hepatic Failure

Journal of Surgical Research

Volumn 134, Issue 2, 2006, Pages 307-314

  Yamamoto, Satoshi ^a   Nguyen, Justin H ^b  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b MAYO CLINIC   (United States)

Author keywords

acute liver failure; BBB permeability; brain edema; gelatinases; TIMP 1

Indexed keywords

EVANS BLUE; GALACTOSAMINE; GELATINASE B; ILOMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; SODIUM CHLORIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; COMATOSE PATIENT; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME ASSAY; EXTRAVASATION; GRAVITY; LIVER FAILURE; MALE; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; RAT; SYSTEMIC CIRCULATION; ZYMOGRAPHY;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN EDEMA; COLLAGENASES; DIPEPTIDES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; ENZYME PRECURSORS; GALACTOSAMINE; INJECTIONS, INTRAPERITONEAL; LIVER FAILURE, ACUTE; MALE; MATRIX METALLOPROTEINASE 9; RATS; RATS, SPRAGUE-DAWLEY; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 33746189720     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2005.11.588     Document Type: Article

References (60)

1. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17 (2001) 463
2. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. structure, function, and biochemistry. Circ Res 92 (2003) 827
3. Baker A.H., Edwards D.R., and Murphy G. Metalloproteinase inhibitors. biological actions and therapeutic opportunities. J Cell Sci 115 (2002) 3719
4. Rosenberg G.A., Estrada E.Y., and Dencoff J.E. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29 (1998) 2189
5. Yong V.W., Krekoski C.A., Forsyth P.A., Bell R., and Edwards D.R. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21 (1998) 75
6. Hartung H.P., and Kieseier B.C. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 107 (2000) 140
7. Romanic A.M., White R.F., Arleth A.J., Ohlstein E.H., and Barone F.C. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats. inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29 (1998) 1020
8. Wang X., Jung J., Asahi M., et al. Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci 20 (2000) 7037
9. Asahi M., Wang X., Mori T., et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21 (2001) 7724
10. Asahi M., Asahi K., Jung J.C., del Zoppo G.J., Fini M.E., and Lo E.H. Role for matrix metalloproteinase 9 after focal cerebral ischemia. effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 20 (2000) 1681
11. Asahi M., Sumii T., Fini M.E., Itohara S., and Lo E.H. Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. Neuroreport 12 (2001) 3003
12. Hoofnagle J.H., Carithers Jr. R.L., Shapiro C., and Ascher N. Fulminant hepatic failure. summary of a workshop. Hepatology 21 (1995) 240
13. Ritt D.J., Whelan G., Werner D.J., Eigenbrodt E.H., Schenker S., and Combes B. Acute hepatic necrosis with stupor or coma. An analysis of thirty-one patients. Medicine 48 (1969) 151
14. Ware A.J., D'Agostino A.N., and Combes B. Cerebral edema. a major complication of massive hepatic necrosis. Gastroenterology 61 (1971) 877
15. Lee W.M. Acute liver failure in the United States. Semin Liver Dis 23 (2003) 217
16. Larsen F.S., and Wendon J. Brain edema in liver failure. basic physiologic principles and management. Liver Transpl 8 (2002) 983
17. Bernal W., Wendon J., Rela M., Heaton N., and Williams R. Use and outcome of liver transplantation in acetaminophen-induced acute liver failure. Hepatology 27 (1998) 1050
18. Silk D.B., and Williams R. Acute liver failure. Br J Hosp Med 22 (1979) 437
19. Vaquero J., and Blei A.T. Etiology and management of fulminant hepatic failure. Curr Gastroenterol Rep 5 (2003) 39
20. Ede R.J., and Williams R.W. Hepatic encephalopathy and cerebral edema. Semin Liver Dis 6 (1986) 107
21. Blei A.T. Pathogenesis of brain edema in fulminant hepatic failure. Prog Liver Dis 13 (1995) 311
22. Dixit V., and Chang T.M. Brain edema and the blood brain barrier in galactosamine-induced fulminant hepatic failure rats. An animal model for evaluation of liver support systems. ASAIO Trans 36 (1990) 21
23. Zimmermann C., Ferenci P., Pifl C., et al. Hepatic encephalopathy in thioacetamide-induced acute liver failure in rats. characterization of an improved model and study of amino acid-ergic neurotransmission. Hepatology 9 (1989) 594
24. Matkowskyj K.A., Marrero J.A., Carroll R.E., Danilkovich A.V., Green R.M., and Benya R.V. Azoxymethane-induced fulminant hepatic failure in C57BL/6J mice. characterization of a new animal model. Am J Physiol 277 (1999) G455
25. Webster S., Gottstein J., Levy R., and Blei A.T. Intracranial pressure waves and intracranial hypertension in rats with ischemic fulminant hepatic failure. Hepatology 14 (1991) 715
26. Wielockx B., Lannoy K., Shapiro S.D., et al. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med 7 (2001) 1202
27. Kleiner D.E., and Stetler-Stevenson W.G. Quantitative zymography. detection of picogram quantities of gelatinases. Anal Biochem 218 (1994) 325
28. Oliver G.W., Leferson J.D., Stetler-Stevenson W.G., and Kleiner D.E. Quantitative reverse zymography. analysis of picogram amounts of metalloproteinase inhibitors using gelatinase A and B reverse zymograms. Anal Biochem 244 (1997) 161
29. Uyama O., Okamura N., Yanase M., Narita M., Kawabata K., and Sugita M. Quantitative evaluation of vascular permeability in the gerbil brain after transient ischemia using Evans blue fluorescence. J Cereb Blood Flow Metab 8 (1988) 282
30. Yepes M., Sandkvist M., Moore E.G., Bugge T.H., Strickland D.K., and Lawrence D.A. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 112 (2003) 1533
31. Marmarou A., Poll W., Shulman K., and Bhagavan H. A simple gravimetric technique for measurement of cerebral edema. J Neurosurg 49 (1978) 530
32. Belanger M., Desjardins P., Chatauret N., and Butterworth R.F. Loss of expression of glial fibrillary acidic protein in acute hyperammonemia. Neurochem Int 41 (2002) 155
33. Traber P.G., Ganger D.R., and Blei A.T. Brain edema in rabbits with galactosamine-induced fulminant hepatitis. Regional differences and effects on intracranial pressure. Gastroenterology 91 (1986) 1347
34. Prontera C., Mariani B., Rossi C., Poggi A., and Rotilio D. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 81 (1999) 761
35. Brown P.D., and Giavazzi R. Matrix metalloproteinase inhibition. a review of anti-tumour activity. Ann Oncol 6 (1995) 967
36. Gijbels K., Galardy R.E., and Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 94 (1994) 2177
37. Solorzano C.C., Ksontini R., Pruitt J.H., et al. A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor alpha (TNF alpha) and abrogates endotoxin-induced lethality. Shock 7 (1997) 427
38. Winding B., NicAmhlaoibh R., Misander H., et al. Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. Clin Cancer Res 8 (2002) 1932
39. Keogh B., Sheahan B.J., Atkins G.J., and Mills K.H. Inhibition of matrix metalloproteinases ameliorates blood-brain barrier disruption and neuropathological lesions caused by avirulent Semliki Forest virus infection. Vet Immunol Immunopathol 94 (2003) 185
40. Trey C., and Davidson C.S. The management of fulminant hepatic failure. In: H P., and F S. (Eds). Progress in liver diseases (1970), Grune & Stratton, New York 282
41. Knudsen G.M., Poulsen H.E., and Paulson O.B. Blood-brain barrier permeability in galactosamine-induced hepatic encephalopathy. No evidence for increased GABA-transport. J Hepatol 6 (1988) 187
42. Livingstone A.S., Potvin M., Goresky C.A., Finlayson M.H., and Hinchey E.J. Changes in the blood-brain barrier in hepatic coma after hepatectomy in the rat. Gastroenterology 73 (1977) 697
43. Horowitz M.E., Schafer D.F., Molnar P., et al. Increased blood-brain transfer in a rabbit model of acute liver failure. Gastroenterology 84 (1983) 1003
44. Knittel T., Mehde M., Grundmann A., Saile B., Scharf J.G., and Ramadori G. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. Histochem Cell Biol 113 (2000) 443
45. Kim T.H., Mars W.M., Stolz D.B., and Michalopoulos G.K. Expression and activation of pro-MMP-2 and pro-MMP-9 during rat liver regeneration. Hepatology 31 (2000) 75
46. Kuyvenhoven J.P., Molenaar I.Q., Verspaget H.W., et al. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury. Thromb Haemost 91 (2004) 506
47. Leu J.I., Crissey M.A., and Taub R. Massive hepatic apoptosis associated with TGF-beta1 activation after Fas ligand treatment of IGF binding protein-1-deficient mice. J Clin Invest 111 (2003) 129
48. Nguyen J.H., Genco P., Castanedes M., and Steers J. Increased matrix metalloproteinase activities in sera of fulminant hepatic failure patients. Am J Transplant 2 Suppl 3 (2002) A858
49. Camacho C., Wharen R., Steers J., and Nguyen J.H. Increased matrix metalloproteinase (MMP)-9 in sera of rats with D-galactosamine-induced fulminant hepatic failure. J Surg Res 100 (2001) P56
50. Kimelberg H.K. Current concepts of brain edema. Review of laboratory investigations. J Neurosurg 83 (1995) 1051
51. Gove C.D., Hughes R.D., Ede R.J., and Williams R. Regional cerebral edema and chloride space in galactosamine-induced liver failure in rats. Hepatology 25 (1997) 295
52. Reif S., Somech R., Brazovski E., et al. Matrix metalloproteinases 2 and 9 are markers of inflammation but not of the degree of fibrosis in chronic hepatitis C. Digestion 71 (2005) 124
53. Galardy R.E., Grobelny D., Foellmer H.G., and Fernandez L.A. Inhibition of angiogenesis by the matrix metalloprotease inhibitor N-[2R-2-(hydroxamidocarbonymethyl)-4-methylpentanoyl)]-L-tryptophan methylamide. Cancer Res 54 (1994) 4715
54. Kawai N., Kawanishi M., Okada M., Matsumoto Y., and Nagao S. Treatment of cold injury-induced brain edema with a nonspecific matrix metalloproteinase inhibitor MMI270 in rats. J Neurotrauma 20 (2003) 649
55. Gardner J., and Ghorpade A. Tissue inhibitor of metalloproteinase (TIMP)-1. the TIMPed balance of matrix metalloproteinases in the central nervous system. J Neurosci Res 74 (2003) 801
56. Nelson A.R., Fingleton B., Rothenberg M.L., and Matrisian L.M. Matrix metalloproteinases. biologic activity and clinical implications. J Clin Oncol 18 (2000) 1135
57. Tambunting F., Beharry K.D., Hartleroad J., Waltzman J., Stavitsky Y., and Modanlou H.D. Increased lung matrix metalloproteinase-9 levels in extremely premature baboons with bronchopulmonary dysplasia. Pediatr Pulmonol 39 (2005) 5
58. Schulze C.J., Wang W., Suarez-Pinzon W.L., Sawicka J., Sawicki G., and Schulz R. Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial [correction of myoctardial] ischemia-reperfusion injury. Circulation 107 (2003) 2487
59. Parsons C.J., Bradford B.U., Pan C.Q., et al. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology 40 (2004) 1106
60. Nakamura T., Ushiyama C., Suzuki S., et al. Effect of plasma exchange on serum tissue inhibitor of metalloproteinase 1 and cytokine concentrations in patients with fulminant hepatitis. Blood Purif 18 (2000) 50